Jawbone Files Antitrust Claim Against Rival Fitbit
Dispute between makers of wearable devices escalates
Valeant Pharmaceuticals (VRX) Stock: No Bottom in Sight
Adam is very bullish on BLUE and the guy is never bullish.
Also meant to add if you do the DD GBT is Sickle Cell and also orphan blood disorders as well.
Sentiment: Strong Buy
Very good PR on the company, this is how BLUE started and hit $180's. GBT better company been around the block.
Article : ( EXEL ) Kidney Cancer Drug Could Revolutionize Treatment
7/22/15 10:30 P.M.
Exelixis reports compelling results in late-stage trials of metastatic kidney cancer drugs.
Although the prognosis for metastatic kidney cancer is disheartening, encouraging late-stage trial data for kidney cancer drugs under development at Exelixis could soon change that, boosting financial results for these companies in the process
Juno Announces FDA Acceptance of New Drug Application for JCAR017 in Relapsed/Refractory B Cell Non-Hodgkin Lymphoma
The drug works by taking the patient's own cells out, essentially training them to fight the cancer cells,then infusing them back into the patient's body. Tests showed a 91 percent remission rate in patients with leukemia and lymphoma
SGYP Catalyst in Late Stage Data ,,,
Tolerability data for Synergy Pharma’s chronic idiopathic constipation treatment top Ironwood’s Linzess.
Synergy Pharmaceuticals ( SGYP ) reported positive data for plecanatide in a Phase 3 study of 1,346patients with chronic idiopathic constipation (CIC). Synergy Pharma’s results are favorably to the results from Ironwood’s two CIC trials. Also importantly, tolerability data to favor plecanatide over Linzess
I would do the DD